BioVie taps investor for $4.74M raise, its latest Nasdaq-priced deal
What's the deal? BioVie, a clinical-stage biopharmaceutical company developing therapies for neurological and neurodegenerative diseases, has priced a $4.74 million offering backed by a single healthcare-focused institutional investor. The raise combines a registered direct offering of 2,962,500 shares at $1.60 each with a concurrent private placement of warrants, both priced at-the-market under Nasdaq rules.
The terms: The concurrent warrants cover up to 2,962,500 shares at an exercise price of $1.70. They become exercisable six months after issuance and expire five and a half years from the issuance date.
What's the money for? BioVie intends to use the net proceeds for working capital and general corporate purposes. The gross figure of roughly $4.74 million is before placement agent commissions and other costs. A.G.P./Alliance Global PartnersDealroom has a profile for this one. Try Dealroom → is acting as sole placement agent, with closing expected on or about November 5, 2026.
What's the endgame? The Nevada-based company is developing bezisterim (NE3107), which targets neuroinflammation and insulin resistance — factors believed to drive Alzheimer's and Parkinson's disease. The drug is also being studied for Long COVID, where persistent inflammation is thought to cause symptoms such as brain fog and fatigue.
The signal: This is a quick re-raise, pulled from a shelf registration the Securities and Exchange Commission declared effective on June 29, 2026. For a cash-hungry clinical-stage developer, a sub-$5 million at-the-market deal is a familiar way to top up working capital without a larger, more dilutive round.
Read more: Business Insider
Image credit: Generated with Gemini
